BACKGROUND Human epidermal growth factor receptor-2(HER-2)plays a vital role in tumor cell proliferation and metastasis.However,the prognosis of HER2-positive gastric cancer is poor.Inetetamab,a novel anti-HER2 target...BACKGROUND Human epidermal growth factor receptor-2(HER-2)plays a vital role in tumor cell proliferation and metastasis.However,the prognosis of HER2-positive gastric cancer is poor.Inetetamab,a novel anti-HER2 targeting drug independently developed in China,exhibits more potent antibody-dependent cell-mediated cytotoxicity than trastuzumab,which is administered as the first-line treatment for HER2-positive gastric cancer in combination with chemotherapy.In this case,the efficacy and safety of inetetamab combined with tegafur was investigated as a second-line treatment for HER2-positive gastric cancer.CASE SUMMARY A 52-year-old male patient with HER2-positive gastric cancer presented with abdominal distension,poor appetite,and fatigue two years after receiving six cycles of oxaliplatin combined with tegafur as first-line treatment after surgery,followed by tegafur monotherapy for six months.The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma.He received 17 cycles of a combination of inetetamab,an innovative domestically developed anti-HER2 monoclonal antibody,and tegafur chemotherapy as the second-line treatment(inetetamab 200 mg on day 1,every 3 wk combined with tegafur twice daily on days 1–14,every 3 wk).Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition and progression-free survival of 17 months.He tolerated the treatment well without exhibiting any grade 3-4 adverse events.CONCLUSION Inetetamab combined with chemotherapy for the treatment of metastatic HER2-positive gastric cancer demonstrates significant survival benefits and acceptable safety.展开更多
Toll样受体家族(Toll like receptors,TLRs)是先天性免疫系统进化过程中形成的非常保守的模式识别受体家族,Toll样受体2(Toll-like receptors 2,TLR2)是已经克隆的Toll样受体家族中表达范围最广,识别病原微生物种类最多的成员。它可单...Toll样受体家族(Toll like receptors,TLRs)是先天性免疫系统进化过程中形成的非常保守的模式识别受体家族,Toll样受体2(Toll-like receptors 2,TLR2)是已经克隆的Toll样受体家族中表达范围最广,识别病原微生物种类最多的成员。它可单独或协同其他Toll样受体家族成员完成对病原体相关分子模式的识别,触发机体对致病微生物的级联免疫应答,尤其是针对细胞毒素的抗炎症反应具有重要的作用,已经成为多种疾病治疗的新靶点。文章对哺乳动物TLR2的分布,结构特征,配体识别,信号转导及其生物学功能的最新研究进展进行了综述。展开更多
基金Supported by the Science and Technology Innovation Development Project of Tai’an,No.2021NS160the Medical and Health Science and Technology Development Plan of Shandong Province,No.202102010647。
文摘BACKGROUND Human epidermal growth factor receptor-2(HER-2)plays a vital role in tumor cell proliferation and metastasis.However,the prognosis of HER2-positive gastric cancer is poor.Inetetamab,a novel anti-HER2 targeting drug independently developed in China,exhibits more potent antibody-dependent cell-mediated cytotoxicity than trastuzumab,which is administered as the first-line treatment for HER2-positive gastric cancer in combination with chemotherapy.In this case,the efficacy and safety of inetetamab combined with tegafur was investigated as a second-line treatment for HER2-positive gastric cancer.CASE SUMMARY A 52-year-old male patient with HER2-positive gastric cancer presented with abdominal distension,poor appetite,and fatigue two years after receiving six cycles of oxaliplatin combined with tegafur as first-line treatment after surgery,followed by tegafur monotherapy for six months.The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma.He received 17 cycles of a combination of inetetamab,an innovative domestically developed anti-HER2 monoclonal antibody,and tegafur chemotherapy as the second-line treatment(inetetamab 200 mg on day 1,every 3 wk combined with tegafur twice daily on days 1–14,every 3 wk).Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition and progression-free survival of 17 months.He tolerated the treatment well without exhibiting any grade 3-4 adverse events.CONCLUSION Inetetamab combined with chemotherapy for the treatment of metastatic HER2-positive gastric cancer demonstrates significant survival benefits and acceptable safety.
文摘Toll样受体家族(Toll like receptors,TLRs)是先天性免疫系统进化过程中形成的非常保守的模式识别受体家族,Toll样受体2(Toll-like receptors 2,TLR2)是已经克隆的Toll样受体家族中表达范围最广,识别病原微生物种类最多的成员。它可单独或协同其他Toll样受体家族成员完成对病原体相关分子模式的识别,触发机体对致病微生物的级联免疫应答,尤其是针对细胞毒素的抗炎症反应具有重要的作用,已经成为多种疾病治疗的新靶点。文章对哺乳动物TLR2的分布,结构特征,配体识别,信号转导及其生物学功能的最新研究进展进行了综述。
